MECHELEN, BELGIUM--(Marketwire - September 24, 2009) -
Mechelen, Belgium and Saffron Walden, UK; 24 September 2009 -
Galapagos NV (Euronext: GLPG) announces today that its service
division, BioFocus DPI, has initiated a drug discovery collaboration
with Schering-Plough Research Institute (SPRI). Under the terms of
the agreement, BioFocus DPI will perform medicinal chemistry with
supporting biology and ADME/PK services for multiple Schering-Plough
drug discovery projects. Total contract value for Galapagos is EUR 2.8
M over a one year period.
Building on a collaboration established in May 2009 and expanded this
month, BioFocus DPI scientists will work with two of SPRI's European
sites on these drug discovery projects.
"We are pleased to build on our collaborative relationship with SPRI,
which has evolved into one of the larger for BioFocus DPI this year
with over 20 research staff currently engaged," said Onno van de
Stolpe, CEO of Galapagos. "BioFocus DPI has proven resilient in
securing large collaborations with strong partners, amidst
consolidation and reorganization in the pharma industry."
About Galapagos and BioFocus DPI
Galapagos (Euronext: GLPG; OTC: GLPYY) is a drug discovery and
development company with small molecule programs in bone and joint
diseases, bone metastasis, cachexia, anti-infectives and metabolic
diseases. Its division BioFocus DPI offers a full suite of
target-to-drug discovery products and services to pharmaceutical and
biotech companies as well as not-for-profit organizations,
encompassing target discovery and validation, screening and drug
discovery through to delivery of pre-clinical candidates. BioFocus
DPI also provides adenoviral reagents for rapid identification and
validation of novel drug targets, compound libraries for drug
screening as well as ADMET products to select compounds. Galapagos
currently employs 495 people and operates facilities in six
countries, with global headquarters in Mechelen, Belgium. More info
at www.glpg.com and www.biofocusdpi.com.
CONTACTS
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com
This release may contain forward-looking statements, including,
without limitation, statements containing the words "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could," "stands to," and "continues," as well as
similar expressions. Such forward-looking statements may involve
known and unknown risks, uncertainties and other factors which might
cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions,
performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of the
date of publication of this document. Galapagos expressly disclaims
any obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation.
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
